Tesamorelin 10 mg

Descripción

Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH) consisting of the full 44-amino-acid GHRH sequence with structural modifications that improve stability and resistance to enzymatic degradation.

Unlike GHRP peptides, which stimulate the ghrelin receptor (GHSR-1a), Tesamorelin acts directly on the GHRH receptor in the anterior pituitary, promoting physiological pulsatile secretion of endogenous growth hormone. This receptor selectivity has made Tesamorelin one of the most thoroughly investigated peptides in growth hormone physiology and metabolic research.

Why Tesamorelin matters in endocrine research

Tesamorelin differs from many secretagogues because it closely mimics the body’s natural GHRH signalling rather than activating ghrelin pathways.

Published research has investigated Tesamorelin in relation to:

• pulsatile growth hormone secretion
• IGF-1 regulation
• body composition
• visceral adipose tissue
• hepatic fat
• endocrine physiology
• metabolic regulation
• pituitary function

Its extensive human evidence base has established Tesamorelin as one of the best-characterised GHRH analogues available for metabolic and endocrine research.

How Tesamorelin works

Unlike GHRP peptides, Tesamorelin activates the growth hormone-releasing hormone receptor (GHRHR).

Published research has explored its relationship with:

Growth hormone secretion

Tesamorelin stimulates physiological pulsatile release of endogenous growth hormone through direct activation of pituitary GHRH receptors.

IGF-1 regulation

Clinical studies consistently demonstrate increased circulating IGF-1 following Tesamorelin administration, making it an important research tool for GH-axis physiology.

Body composition

A major area of investigation has been the relationship between endogenous GH stimulation and changes in visceral adipose tissue and lean body mass.

Metabolic physiology

Researchers have also investigated hepatic fat metabolism, lipid regulation and broader metabolic adaptations associated with physiological GH release.

Why Tesamorelin is widely investigated in metabolic research

Among growth hormone secretagogues, Tesamorelin occupies a unique position because much of its research has focused on metabolic health rather than growth hormone deficiency alone.

Published studies have explored:

• visceral adipose tissue
• hepatic fat
• body composition
• metabolic syndrome
• IGF-1 physiology
• endocrine regulation
• HIV-associated lipodystrophy

This broad clinical evidence has made Tesamorelin one of the most important peptides for studying the interaction between the growth hormone axis and metabolic physiology.

Investigación humana y preclínica

Tesamorelin has one of the strongest clinical evidence bases among all growth hormone secretagogues.

Multiple Phase III studies have investigated its effects on growth hormone secretion, visceral adipose tissue, lipid metabolism and hepatic fat. Unlike many research peptides, Tesamorelin has also received regulatory approval for one specific clinical indication, resulting in extensive long-term human safety and efficacy data.

How Tesamorelin differs from other GH secretagogues

Tesamorelin

• GHRH analogue
• Direct GHRH receptor activation
• Strong clinical evidence
• Extensive metabolic research

CJC-1295 (No DAC)

• GHRH analogue
• Longer research half-life
• Primarily experimental

Ipamorelin

• Ghrelin receptor agonist
• Selective GH secretagogue
• Minimal appetite effects

GHRP-2

• Potent ghrelin receptor agonist
• Robust GH pulses
• Endocrine physiology

GHRP-6

• Ghrelin receptor agonist
• Appetite and GH research
• Gastrointestinal physiology
• Published safety observations

Published clinical studies have generally reported Tesamorelin to be well tolerated. The most commonly reported adverse events included injection-site reactions, arthralgia, peripheral oedema and transient increases in IGF-1, with gastrointestinal effects occurring less frequently than with many modern metabolic peptides. Safety findings are derived from controlled clinical trials conducted primarily in patients with HIV-associated lipodystrophy.

Características del producto

Aplicación: investigación de laboratorio y análisis
Uso restringido: no apto para consumo humano; no apto para uso médico, veterinario o cosmético
Producido en instalaciones que cumplen con GMP bajo estrictos protocolos de control de calidad.
Cada lote se somete a pruebas de laboratorio exhaustivas después de la producción (puede encontrar el Certificado de Análisis debajo de las imágenes del producto).
Liofilizado (liofilizado) para máxima estabilidad y vida útil prolongada.
Sellado en viales estériles, listo para la reconstitución.
Purity: ≥ 99% (HPLC)
Apariencia: polvo blanco liofilizado
Fórmula molecular: C₂₂₁H₃₆₆N₇₂O₆₇S
Molecular weight: 5135.78
CAS No: 218949-48-5

Almacenamiento: los viales liofilizados sin abrir se almacenan mejor refrigerar a 2–8 °C, que es el método de almacenamiento confirmado por nuestro socio de fabricación y adecuado para hasta 24 meses. Se prefiere la refrigeración porque minimiza los ciclos innecesarios de congelación y descongelación durante la manipulación rutinaria. Si se requiere un almacenamiento a más largo plazo, los viales liofilizados sin abrir también pueden mantenerse congelados. Una vez reconstituidos, almacene siempre a 2–8 °C y no congele.

Reconstitución y manipulación

Tesamorelin is supplied as a lyophilised vial and should be handled using standard peptide reconstitution procedures appropriate to the research setting. Must be reconstituted with agua bacteriostática antes de usar. Para ayudar a preservar la integridad estructural, agregue el disolvente elegido lentamente contra la pared interior del vial en lugar de directamente sobre el péptido en polvo, y evite agitar vigorosamente. La agitación suave suele ser suficiente una vez que el péptido se ha disuelto por completo. La práctica estándar de laboratorio también incluye permitir que los viales refrigerados alcancen la temperatura ambiente antes de la reconstitución para minimizar la condensación dentro del vial.

Para otras guías sobre selección de solventes, planificación de concentraciones y almacenamiento, consulte el completo Guía de Reconstitución de Péptidos y Calculadora de Reconstitución.

Estudios clave publicados

• Falutz J, Allas S, Blot K, et al. Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. New England Journal of Medicine, 2007.

The pivotal Phase III study demonstrating reductions in visceral adipose tissue following Tesamorelin treatment while preserving lean body mass.

• Stanley TL, Feldpausch MN, Oh J, et al. Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation. JAMA, 2014.

A landmark study showing reductions in visceral and hepatic fat, expanding Tesamorelin research into metabolic liver physiology.

• Spooner LM, et al. Tesamorelin: A Growth Hormone-Releasing Factor Analogue for HIV-Associated Lipodystrophy. Drugs, 2012.

A comprehensive review covering pharmacology, mechanism of action and clinical development of Tesamorelin.

• Badran AS, et al. Body Composition, Hepatic Fat, Metabolic and Safety Outcomes of Tesamorelin: A Meta-analysis of Randomized Controlled Trials. Obesity Research & Clinical Practice, 2026.

A recent meta-analysis summarising clinical evidence for body composition, liver fat and metabolic outcomes across Tesamorelin trials.

Preguntas Frecuentes

What is Tesamorelin?

Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland through the GHRH receptor, promoting physiological pulsatile release of endogenous growth hormone. It is widely investigated in endocrine and metabolic research involving the GH/IGF-1 axis, body composition and visceral adipose tissue.

How does Tesamorelin differ from CJC-1295?

Both Tesamorelin and CJC-1295 are GHRH analogues that activate the same receptor pathway. Tesamorelin has an extensive clinical evidence base, including regulatory approval for HIV-associated lipodystrophy, whereas CJC-1295 remains primarily an experimental research peptide. Their receptor mechanism is similar, but their clinical development differs substantially.

How does Tesamorelin differ from Ipamorelin or GHRP peptides?

Tesamorelin stimulates growth hormone release through the GHRH receptor, while Ipamorelin, GHRP-2 and GHRP-6 activate the ghrelin receptor (GHSR-1a). These are complementary physiological pathways, which is why GHRH analogues and GHRP peptides are frequently investigated together in endocrine research.

Why is Tesamorelin widely investigated in metabolic research?

Beyond growth hormone physiology, Tesamorelin has been extensively studied for its effects on body composition, visceral adipose tissue, hepatic fat, lipid metabolism and IGF-1 regulation. This broad clinical evidence distinguishes it from many other growth hormone secretagogues.

What research areas commonly investigate Tesamorelin?

Published studies have investigated Tesamorelin in growth hormone secretion, IGF-1 regulation, pituitary physiology, body composition, visceral adipose tissue, hepatic fat, metabolic regulation and endocrine signalling.

Can Tesamorelin be combined with GHRP peptides in research?

Yes. Because Tesamorelin activates the GHRH receptor while GHRP peptides activate the ghrelin receptor, researchers frequently investigate these pathways together to study complementary mechanisms regulating pulsatile growth hormone secretion. Individual study designs vary, and findings should be interpreted within the context of the published research.

¿Está este producto destinado al uso humano?

No. Tesamorelin supplied by LIFE Peptide is provided strictly for laboratory and analytical research. It is not intended for human consumption, diagnosis, treatment or prevention of disease. Any discussion of published studies summarises the scientific literature relating to the Tesamorelin molecule rather than the intended use of this product.

Contexto de investigación relacionado

Tesamorelin belongs to the GHRH analogue and growth hormone signaling research class, which includes peptides investigated for endocrine regulation, GH-axis modulation, and pulsatile hormone release mechanisms.
For a broader overview of GH signaling pathways and comparative peptide mechanisms, see our Growth hormone peptides research guide.
Researchers studying GH-axis interaction may also examine:

CJC-1295 (no DAC)
Ipamorelin
GHRP-2
GHRP-6

Explorar todos los compuestos en el Growth hormone secretagogues category.
Researchers investigating endocrine regulation may also explore compounds in the Metabolic research category, including GLP-1 and multi-pathway incretin agonists.

NOTA: Esto es solo para fines de referencia educativa y no constituye asesoramiento médico.

Descargo de responsabilidad
Este producto se vende únicamente para fines de investigación. No está destinado a diagnosticar, tratar, curar ni prevenir ninguna enfermedad. El comprador asume toda la responsabilidad por su manipulación y uso adecuados.